– USA, CA – Vesica Health Inc., a multi-omics, liquid biopsy company transforming the management of hematuria patients and improving the early detection of bladder cancer, today announced the appointments of Dr. Jan Groen, Mark McDonough, and Joe Sollee to its Board as Independent Directors, bringing proven executive leadership, strategic and commercial experience to the Board.
Dr. Groen will serve as Chairman of the Board of Directors.
About Dr. Jan Groen, Chair of the Board
Dr. Groen is the Chairman & CEO of Intravacc (The Netherlands) a contract development & manufacturing organization for the development of innovative human vaccines. His career spans many years in biotechnology, formerly as CEO at MDxHealth (MDXH), where he established the company as a market-leading molecular diagnostic uro-oncology company in the U.S. and EU. Earlier, as the President and COO of Agendia, responsible for the diagnostic operations in the U.S. and EU, he led the introduction of the first FDA-cleared breast cancer recurrence assay in the U.S. He served as VP of Research & Development at Focus Diagnostics, a subsidiary of Quest Diagnostics in California, and co-founded ViroClinics B.V. and DxOrange B.V. He has held numerous scientific leadership positions at the Erasmus Medical Center, RIVM (National Institute of Public Health, NL) and Akzo-Nobel. Previously, Dr, Groen served on the Board of IBL-International (DE) and MyCartis (BE), presently serves as Chairman of the Board at Cergentis (NL), and currently as Independent Director at Novigenix (CH), and Chairman of the Board member Angle Plc. (UK).
About Mark McDonough, Independent Director
Mr. McDonough is the CEO and Board member of ChromaCode, Inc., a genomics multiplexing company that leverages their High-Definition PCR platform to enable comprehensive, fast, less expensive testing solutions. Previously, he served as CEO of PierianDx where he raised ~$48M to fund the company’s growth initiatives and completed an exit to Summa Equity which resulted in the formation of Velsera. Mr. McDonough served as President, CEO, and Board member for Immunis.AI, a privately held pre-commercial liquid biopsy platform company, and at CombiMatrix, a publicly traded company and leader in high-complexity reproductive health testing. At CombiMatrix, he successfully led the company’s turnaround growth and ultimately orchestrated its sale in November 2017. Earlier, he served in various leadership roles at high-growth diagnostic companies including US LABS (acquired by LabCorp) and Ventana Medical Systems (acquired by Roche). Mr. McDonough is a proud former Naval Officer having served as a Navigator and Communications Officer on the USS FLETCHER (DD 992).
About Joe Sollee, Independent Director
Mr. Sollee is EVP of Corporate Development and General Counsel at MDxHealth and has more than 20 years of experience in the healthcare industry, including senior management roles in both private and publicly listed pharmaceuticals, health information technology, and molecular diagnostics companies. He has served as chief legal counsel to MDxHealth since its inception in 2003. Before MDxHealth, he led the Life Sciences Practice Group at the law firm of Kennedy Covington (now K&L Gates) and held senior legal and management positions at TherapyEdge and Triangle Pharmaceuticals. In addition, he has practiced as a corporate attorney in the Washington D.C. legal firm Swidler & Berlin and as an investment banker at Smith Barney in New York. Mr. Sollee received a Juris Doctorate in Law and a master’s degree in international law from Duke University, a BA degree from Harvard University, and has been awarded New York, Washington D.C., and North Carolina legal bar certifications.
About Vesica Health, Inc.
Vesica Health’s mission is to transform the management of hematuria patients and improve the early detection of bladder cancer. Each year it is estimated that upwards of 17M (1-in-5) adults will present with hematuria, the primary symptom of bladder cancer, yet despite guideline recommendations only ~12% of patients are referred to urology for clinical evaluation. As a consequence, ~20% of bladder cancers are missed each year, leading to later-stage disease at diagnosis and higher mortality. Vesica has translated 20 years of advanced multi-omics research in bladder cancer into a well-validated, commercial-ready precision diagnostic test to improve the evaluation of hematuria, early detection of disease, and recurrence monitoring.
For more information: https://www.vesicahealth.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.